Washed Microbiota Transplantation for Allergic Rhinitis

Condition(s) studied

Investigational drug(s) / intervention(s)

Washed Microbiota Transplantation: Patients take four capsules containing washed microbiota once a day for five consecutive days

Placebo: Patients take four capsules in the same packaging as the experimental group once a day for five consecutive days

Study summary

Allergic rhinitis (AR) is characterized by sneezing, nasal congestion, nasal itching and nasal leakage and is caused by immunoglobulin E (IgE)-mediated reactions to inhaled allergens. Increasing evidence showed that gut microbiota could influence the development of AR, and we found that washed microbiota transplantation (WMT) could improve nasal symptoms in clinical practice. This clinical trial aims to evaluate the efficacy and safety of WMT for AR.

Eligibility

Primary outcome measure(s)

• Changes in the reflective total nasal symptom score (rTNSS) — baseline, one weeks, four weeks, twelve weeks post WMT
  TNSS is expressed as the sum of the scores for the four nasal symptoms (nasal congestion, rhinorrhea, nasal itching, and sneezing) in the past 12 hours. Each symptom was rated on a 4-point scale from 0 (none) through 1 (mild), 2 (moderate), and 3 (severe).

Trial sites (1)

More The Second Hospital of Nanjing Medical University trials in China

Other trials for the same condition